Allogeneic T-cell Immunotherapy Company - Atara Biotherapeutics
Sep 3, 2024 · Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases.
Pipeline - Atara Biotherapeutics
Atara Biotherapeutics’s robust, late-stage pipeline features a host of potentially transformative T-cell immunotherapies for cancer, autoimmune and viral diseases.
Atara Biotherapeutics, Inc. (ATRA) - Yahoo Finance
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the...
Atara Biotherapeutics (ATRA)
Nov 12, 2024 · Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly …
Atara Biotherapeutics Provides Update on Clinical Programs …
5 days ago · About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and …
Atara hit with cell therapy clinical hold after FDA inspection
5 days ago · After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline of T-cell immunotherapies. | Atara announced that the …
US FDA declines to approve Atara Biotherapeutics' cancer therapy
Jan 16, 2025 · The U.S. Food and Drug Administration on Thursday declined to approve Atara Biotherapeutics' therapy to treat patients with a rare cancer that develops after organ or stem …
Atara Biotherapeutics Provides Regulatory and Business Update …
Jan 16, 2025 · Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform
About - T-Cell Immunotherapy Technology Platform - Atara Biotherapeutics
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases.
Atara Biotherapeutics (ATRA): Another Dip Buying Opportunity …
Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is rated as a Buy.
- Some results have been removed